Searched for
CIDMUS
Market volatility derails Novartis' plan to sell stake in its India armNovartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strate...- Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy'sCipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- What triggered Lupin’s growth spurt & can it be sustained?"From Q2 onwards, we expected to get back to double digit growth and are very happy that it is happening in Q1 itself. The growth year on y...
- Analysts bearish on 'expensive' Lupin after Q3 disappoints, stock falls 9%Of the 44 analysts, 18 of them have a 'sell' rating while 15 remain neutral. On aggregate, analysts slashed consensus price targets by 4.35...
- Novartis heart drug price may fall by 60% on generic rollouts"At least 30-40 generic brands are expected to hit the market next in a couple of weeks," said Hari Natarajan, managing director, Pronto Co...
- Dr Reddy's cuts price of cardiovascular drug Cidmus"Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs 78.32); Rs 49 for 100 mg (down from Rs 83.86); Rs 79...
- Intas & Dr Reddy's in race with PEs to buy US' AthenexAthenex, which is into the development of cell therapies to treat cancers, had hired investment advisory firm Cowen Inc to run a formal pro...
- Buy Dr. Reddy's Laboratories, target price Rs 4900: Prabhudas LilladherDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 72169.74 Crore) operating i...
- Indian pharma chases growth with niche home buys, tie-ups as US booster fadesThe US market with its headwinds related to increased competitive intensity, pricing pressures and high regulations, has not remained as lu...
- Stocks in the news: Infosys, IOC, Maruti Suzuki, Power Grid, HDFC and LupinAuto manufacturers, which have announced their sales numbers for the month of March, will remain under focus.
- Dr Reddy's buys Novartis cardiovascular brand Cidmus in India for Rs 456 croreDr. Reddy’s will look to leverage its wide base to engage with healthcare professionals, and to significantly enhance the reach of the prod...
- Natco dares Novartis with new heart drugAccording to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...
Load More
